Stock Track | Innoviva Soars 14% as Cantor Fitzgerald Reaffirms Buy Rating with $31 Price Target

Stock Track11-07

Innoviva (INVA) shares surged 13.99% in intraday trading on Thursday, propelled by a bullish analyst report from Cantor Fitzgerald. The biopharmaceutical company's stock rally comes as investors react positively to the reaffirmed confidence from Wall Street.

Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Innoviva and set an ambitious price target of $31.00. This target represents a significant upside potential from the stock's previous closing price, indicating strong confidence in the company's future prospects. The firm also reiterated its Overweight rating on Innoviva, further underlining its positive outlook on the stock.

The substantial price movement puts Innoviva on track for its largest percentage increase since February 10, 2022. The stock has been showing momentum recently, rising in five of the past six trading sessions. Year-to-date, Innoviva is up 19.14%, outperforming many of its peers in the healthcare sector. As the market digests this latest vote of confidence from analysts, investors will be watching closely to see if Innoviva can maintain this upward trajectory and approach Cantor Fitzgerald's bullish price target.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1184470943?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 02:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1184470943","market":"sg","top_or_hot":-1,"title":"Stock Track | Innoviva Soars 14% as Cantor Fitzgerald Reaffirms Buy Rating with $31 Price Target","media":"Stock Track","content":"<p>Innoviva (INVA) shares surged 13.99% in intraday trading on Thursday, propelled by a bullish analyst report from Cantor Fitzgerald. The biopharmaceutical company's stock rally comes as investors react positively to the reaffirmed confidence from Wall Street.</p>\n\n<p>Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Innoviva and set an ambitious price target of $31.00. This target represents a significant upside potential from the stock's previous closing price, indicating strong confidence in the company's future prospects. The firm also reiterated its Overweight rating on Innoviva, further underlining its positive outlook on the stock.</p>\n\n<p>The substantial price movement puts Innoviva on track for its largest percentage increase since February 10, 2022. The stock has been showing momentum recently, rising in five of the past six trading sessions. Year-to-date, Innoviva is up 19.14%, outperforming many of its peers in the healthcare sector. As the market digests this latest vote of confidence from analysts, investors will be watching closely to see if Innoviva can maintain this upward trajectory and approach Cantor Fitzgerald's bullish price target.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Innoviva Soars 14% as Cantor Fitzgerald Reaffirms Buy Rating with $31 Price Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Innoviva Soars 14% as Cantor Fitzgerald Reaffirms Buy Rating with $31 Price Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-07 02:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Innoviva (INVA) shares surged 13.99% in intraday trading on Thursday, propelled by a bullish analyst report from Cantor Fitzgerald. The biopharmaceutical company's stock rally comes as investors react positively to the reaffirmed confidence from Wall Street.</p>\n\n<p>Cantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Innoviva and set an ambitious price target of $31.00. This target represents a significant upside potential from the stock's previous closing price, indicating strong confidence in the company's future prospects. The firm also reiterated its Overweight rating on Innoviva, further underlining its positive outlook on the stock.</p>\n\n<p>The substantial price movement puts Innoviva on track for its largest percentage increase since February 10, 2022. The stock has been showing momentum recently, rising in five of the past six trading sessions. Year-to-date, Innoviva is up 19.14%, outperforming many of its peers in the healthcare sector. As the market digests this latest vote of confidence from analysts, investors will be watching closely to see if Innoviva can maintain this upward trajectory and approach Cantor Fitzgerald's bullish price target.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"INVA","symbol_name":"Innoviva, Inc.","start_time":0,"source_url":"","article_id":"1184470943","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1184470943","pubTimestamp":1762452304,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Innoviva (INVA) shares surged 13.99% in intraday trading on Thursday, propelled by a bullish analyst report from Cantor Fitzgerald. The biopharmaceutical company's stock rally comes as investors...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"INVA":"Innoviva, Inc."},"translate_title":"股票追踪|Cantor Fitzgerald重申买入评级，目标价31美元，Innoviva飙升14%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVA":1},"content_text":"Innoviva (INVA) shares surged 13.99% in intraday trading on Thursday, propelled by a bullish analyst report from Cantor Fitzgerald. The biopharmaceutical company's stock rally comes as investors react positively to the reaffirmed confidence from Wall Street.\nCantor Fitzgerald analyst Steven Seedhouse maintained a Buy rating on Innoviva and set an ambitious price target of $31.00. This target represents a significant upside potential from the stock's previous closing price, indicating strong confidence in the company's future prospects. The firm also reiterated its Overweight rating on Innoviva, further underlining its positive outlook on the stock.\nThe substantial price movement puts Innoviva on track for its largest percentage increase since February 10, 2022. The stock has been showing momentum recently, rising in five of the past six trading sessions. Year-to-date, Innoviva is up 19.14%, outperforming many of its peers in the healthcare sector. As the market digests this latest vote of confidence from analysts, investors will be watching closely to see if Innoviva can maintain this upward trajectory and approach Cantor Fitzgerald's bullish price target.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1184470943","isCrawlerRequest":true}